Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

BridgeBio Pharma (BBIO) Revenue (2019 - 2025)

BridgeBio Pharma (BBIO) has disclosed Revenue for 7 consecutive years, with $154.2 million as the latest value for Q4 2025.

  • Quarterly Revenue rose 2521.18% to $154.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $502.1 million through Dec 2025, up 126.26% year-over-year, with the annual reading at $502.1 million for FY2025, 126.26% up from the prior year.
  • Revenue hit $154.2 million in Q4 2025 for BridgeBio Pharma, up from $120.7 million in the prior quarter.
  • In the past five years, Revenue ranged from a high of $211.1 million in Q1 2024 to a low of $338000.0 in Q3 2022.
  • Historically, Revenue has averaged $41.6 million across 5 years, with a median of $3.4 million in 2023.
  • Biggest five-year swings in Revenue: plummeted 97.77% in 2023 and later skyrocketed 11461.88% in 2024.
  • Year by year, Revenue stood at $10.0 million in 2021, then tumbled by 81.3% to $1.9 million in 2022, then dropped by 6.68% to $1.7 million in 2023, then soared by 237.08% to $5.9 million in 2024, then soared by 2521.18% to $154.2 million in 2025.
  • Business Quant data shows Revenue for BBIO at $154.2 million in Q4 2025, $120.7 million in Q3 2025, and $110.6 million in Q2 2025.